A New Headset to Help With Depression Is Now Available in the US

This headset offers a new, drug-free option for depression treatment that can be used at home.

Flow Neuroscience, a Swedish firm, has launched a new headset in the US designed to help treat depression. The device, which received FDA approval in December, is worn on the forehead for 30 minutes daily and uses low-intensity electrical stimulation on the left frontal lobe of the brain, an area associated with mood regulation. This approach targets reduced brain activity observed in individuals with depression, aiming to be an alternative or supplement to antidepressant medications. A clinical trial showed that 45% of participants using the Flow device experienced symptom remission over 10 weeks, compared to 22% in a control group. While similar in brain stimulation area to TMS, Flow's headset offers home use convenience. The device is available via prescription and telehealth, with a 10-week course costing $2,200 plus a $325 monthly subscription, and Flow is seeking insurance reimbursement.

The introduction of Flow's headset marks a significant step in the growing market of brain-stimulating wearables, suggesting a future where non-pharmacological treatments for mental health conditions become more accessible. While costing substantially more upfront than traditional antidepressants, its convenience and potential to reduce reliance on medication could appeal to a segment of patients seeking alternatives. The success of this device may pave the way for further innovation in at-home neurological therapies.

The high price point and out-of-pocket nature of the Flow headset in the US may limit its immediate widespread adoption, contrasting with the insurance-covered accessibility of most antidepressants. However, Flow's efforts to secure insurance reimbursement and the growing interest from venture capitalists like Vinod Khosla in nonchemical treatments signal a potential shift in how mental health conditions are addressed. Future adoption will likely depend on long-term efficacy data and the company's ability to navigate the US healthcare reimbursement landscape.